Statistiche di base
| LEI | 549300U5ISIWCBXD6W77 |
| CIK | 1842952 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Context Therapeutics Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi |
|
| August 6, 2025 |
, between Context Therapeutics Inc. and Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 9th day of June, 2025 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Karen Chagin, M.D. (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capitalized words not immediately defined shall |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE |
|
| August 6, 2025 |
Context Therapeutics Inc. and Dr. K Exhibit 10.1 Context Therapeutics 2001 Market St, Suite 3915, Unit#15 Philadelphia, PA 19103 April 30, 2025 Dr. Karen Smith [***] Dear Dr. Smith: On behalf of Context Therapeutics Inc. (the “Company”), I am very pleased to offer you the position of Interim Chief Medical Officer, reporting to the Chief Executive Officer. The initial terms of employment are as follows: ■Base Pay: You will be paid an |
|
| August 6, 2025 |
Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”), made as of June 1, 2025 (the “Effective Date”), is by and between Context Therapeutics Inc., a Delaware corporation with an office address at 2001 Market Street, Suite 3915, Unit#15, Philadelphia, PA 19103 (“Company”), and Dr. Karen Smith, with an address of [***] (hereinafter “Consultant”). PREAMBLE WHEREAS, Company de |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| June 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| June 2, 2025 |
June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 9, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| April 9, 2025 |
Exhibit 99.1 Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, PA, April 9, 2025 - Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers fo |
|
| April 4, 2025 |
Table of Contents PRELIMINARY COPY DATED APRIL 4, 2025, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci |
|
| March 20, 2025 |
As Filed with the Securities and Exchange Commission on March 20, 2025 As Filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Description of Securities of Context Therapeutics Inc. Exhibit 4.4 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2024, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share. The fol |
|
| March 20, 2025 |
Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CONFIDENTIAL EXECUTION VERSION FIRST AMENDMENT TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT This First Amendment to Development and Manufacturing Services Agreement (this “First Amen |
|
| March 20, 2025 |
(as assigned to the Company on July Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL MASTER SERVICES AGREEMENT TABLE OF CONTENTS 2. SCOPE OF THE AGREEMENT 11 2.1. Scope of Agreement 11 2.2. Statements of Work 11 2.2.1. Current Statement of Work 11 2.3. Change Orders 12 2.4. |
|
| March 20, 2025 |
ontext Therapeutics Inc. Insider Tradi Exhibit 19 CONTEXT THERAPEUTICS INC. INSIDER TRADING POLICY Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Context Therapeutics Inc. (together with its subsidiaries, the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Dir |
|
| February 28, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis |
|
| February 14, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| January 14, 2025 |
Exhibit 99.1 Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, PA— January 14, 2025—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engage |
|
| January 14, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| January 13, 2025 |
Exhibit 99.1 Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, PA— January 13, 2025—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical co |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis |
|
| December 2, 2024 |
December 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Exhibit 99. |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| December 2, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268266 PROSPECTUS SUPPLEMENT (To Prospectus dated November 16, 2022) $75,000,000 Common Stock We have entered into a Sales Agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement. In accordance with th |
|
| December 2, 2024 |
Exhibit 10.1 CONTEXT THERAPEUTICS INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT December 2, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Context Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issu |
|
| November 14, 2024 |
CNTX / Context Therapeutics Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
CNTX / Context Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment SC 13G 1 ef20038670sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 14, 2024 |
CNTX / Context Therapeutics Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1153050813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 12, 2024 |
Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-283037 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX |
|
| November 6, 2024 |
CNTX / Context Therapeutics Inc. / Hudson Bay Capital Management LP - CNTX 13G/A Passive Investment SC 13G/A 1 cntx13ga.htm CNTX 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| November 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Context Therapeutics Inc. |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Exhibit 4.3 CONTEXT THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. E |
|
| September 23, 2024 |
, 2024, by and between the Company and CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10. |
|
| September 23, 2024 |
September 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| September 23, 2024 |
Exhibit 99.1 BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $ |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi |
|
| September 17, 2024 |
endment to the Amended and Restated Certificate of Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), hereby certifies as follows: FIRST: By unanimous written consent, the Board of Directors approved a proposed amendment to the Amended and Restated Certificate |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi |
|
| September 17, 2024 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. (Composite document reflecting amendments through September 17, 2024) ARTICLE I. The name of the Company is Context Therapeutics Inc. ARTICLE II. The purpose of this company is to engage in any lawful act or activity for which companies may be organized under the General Corporation Law of Delaware. ARTICLE |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis |
|
| September 4, 2024 |
Exhibit 99.1 Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy PHILADELPHIA, PA— September 4, 2024—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceuti |
|
| August 7, 2024 |
Agreement under the Context Therapeutics Inc. 2021 Long-Term Incentive Plan Exhibit 10.6 Context Therapeutics Inc. 2021 Long -Term Performance Incentive Plan Stock Option Agreement 1.A Stock Option (the “Option”) for a total of [•] shares of $0.001 par value per share of Common Stock (the “Stock”) of Context Therapeutics Inc. (the “Company”), is hereby granted to [•] (the “Optionee”), subject to the terms and provisions of the Context Therapeutics Inc. 2021 Long-Term Perf |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE |
|
| August 7, 2024 |
Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 1st day of August, 2024 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Claudio Alberto Dansky Ullmann, M.D. (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capitalized words not immed |
|
| August 7, 2024 |
Form of Stock Option Agreement (Inducement Grant) of Context Therapeutics Inc. Exhibit 10.5 Context Therapeutics Inc. Stock Option Agreement (Inducement Grant) 1.A Stock Option (the “Option”) for a total of [•] shares of $0.001 par value per share of Common Stock (the “Stock”) of Context Therapeutics Inc. (the “Company”), is hereby granted to [•] (the “Optionee”), subject to the terms and provisions of this Stock Option Agreement (this “Agreement”) and the Context Therapeuti |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 12, 2024 |
Table of Contents PRELIMINARY COPY DATED JULY 12, 2024, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| July 10, 2024 |
a2024july-contextxcorpde July 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| July 10, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10. |
|
| July 10, 2024 |
Exhibit 99.1 Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, PA— July 10, 2024—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| June 5, 2024 |
CNTX / Context Therapeutics Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 31, 2024 |
64,515,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-279693 PROSPECTUS 64,515,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders” on page 10 of up to 64,515,000 shares of our common stock, including up to 5,482,741 shares of common stock i |
|
| May 29, 2024 |
Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 May 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-279693 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rule |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024. As filed with the Securities and Exchange Commission on May 24, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 86-3738787 (State or other jurisdiction of incorporation or organization) (IRS Em |
|
| May 24, 2024 |
CNTX / Context Therapeutics Inc. / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment SC 13G 1 tm2415543d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 21077P108 (CUSIP Number) May 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Context Therapeutics Inc. |
|
| May 13, 2024 |
CNTX / Context Therapeutics Inc. / Avidity Partners Management LP Passive Investment SC 13G 1 d1104605913-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) May 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| May 10, 2024 |
CNTX / Context Therapeutics Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH |
|
| May 2, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 1, 2024 (the “Agreement Date”), by and between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursu |
|
| May 2, 2024 |
May 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| May 2, 2024 |
Exhibit 99.2 Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, PA— May 2, 2024 - Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advanci |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission F |
|
| May 2, 2024 |
Exhibit 99.1 Context Therapeutics Announces $100 Million Private Placement Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, PA— May 2, 2024 - Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for sol |
|
| May 2, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 1, 2024 (the “Agreement Date”), between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t |
|
| May 2, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| April 1, 2024 |
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers Important Regulatory Milestone Supports Next Phase of CTIM-76 Development PHILADELPHIA, PA— April 1, 2024 - Context Therapeutics Inc. |
|
| March 21, 2024 |
Description of Securities of Context Therapeutics Inc. Exhibit 4.3 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2023, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share. The fol |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci |
|
| March 21, 2024 |
Exhibit 97 CONTEXT THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Effective May 30, 2023 Policy The Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”) has adopted this Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission regulations promulgat |
|
| March 21, 2024 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on March 19, 2024) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures 2 2.5 Notice Of Stockholders’ Meetings 8 2.6 Quorum 8 2.7 |
|
| March 21, 2024 |
As Filed with the Securities and Exchange Commission on March 21, 2024 As Filed with the Securities and Exchange Commission on March 21, 2024 Registration No. |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio |
|
| March 21, 2024 |
US.361564558.01361564558.03 - i - AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on October 21, 2021 and effective as of theMarch 19, 2024) closing of the Company’s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting |
|
| March 6, 2024 |
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis |
|
| March 6, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 29th day of February, 20 |
|
| February 13, 2024 |
SC 13G/A 1 contextsc13ga-123123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt |
|
| February 7, 2024 |
CNTX / Context Therapeutics Inc. / Lehr Martin A. - SC 13G/A Passive Investment SC 13G/A 1 cntx-schedule13gamlehr.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| January 5, 2024 |
CNTX / Context Therapeutics Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address, and Telephone Number of Person Authorized to Receive |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX |
|
| October 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| October 31, 2023 |
November 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| October 31, 2023 |
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented at SITC 38th Annual Meeting on November 3rd PHILADELPHIA, PA— October 31, 2023—Context Therapeutics Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE |
|
| August 7, 2023 |
a2023augcontextxcorppre August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| June 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH |
|
| April 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2023 |
Table of Contents PRELIMINARY COPY DATED MARCH 27, 2023, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 22, 2023 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 20 day of March, 2023 ( |
|
| March 22, 2023 |
As Filed with the Securities and Exchange Commission on March 22, 2023 As Filed with the Securities and Exchange Commission on March 22, 2023 Registration No. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio |
|
| March 22, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC. |
|
| March 22, 2023 |
a2023marcontextxcorppre March 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| March 22, 2023 |
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, PA— March 22, 2023—Context Therapeutics Inc. |
|
| March 22, 2023 |
Description of Securities of Context Therapeutics Inc. Exhibit 4.3 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share (the “Co |
|
| March 22, 2023 |
Exhibit 10.24 TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of 21 March 2023 (the “Termination Effective Date”), is by and between Context Therapeutics Inc., having a place of business at 2001 Market Street, Suite 3915, Unit# 15, Philadelphia, PA 19103 US |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci |
|
| February 14, 2023 |
CNTX / Context Therapeutics Inc. / Context Therapeutics Inc. - SC 13G Passive Investment SC 13G 1 cntx-schedule13glehr14feb23.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| February 6, 2023 |
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, PA— February 6, 2023—Context Therapeutics Inc. |
|
| February 6, 2023 |
a2023febcontextxcorppre February 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| January 9, 2023 |
CNTX / Context Therapeutics Inc. / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No.1 Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 21077P108 (CUSIP Number) January 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 4, 2023 |
contextcorppresentationj January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| January 4, 2023 |
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, PA— Jan. |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi |
|
| December 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| December 8, 2022 |
EX-99.1 2 cntxsabcsdatarelease12722.htm EX-99.1 Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing |
|
| December 1, 2022 |
a20221201cldn6rdwebinar- December 1, 2022 Identification of CTIM-76, a CLDN6 x CD3 bispecific antibody Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis |
|
| December 1, 2022 |
EX-99.1 2 a20221129-contexttherapeut.htm EX-99.1 Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, PA — November 29, 2022—Context Therap |
|
| November 14, 2022 |
5,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS 5,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 10 of up to 5,000,000 shares of our common stock. The selling stockholders or their permitted transfer |
|
| November 14, 2022 |
Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 CORRESP 1 filename1.htm Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268266 Ladies and Gentlemen: Pursuant to Rule 461 of Reg |
|
| November 9, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the “Prospectus”), related to the disposition, from time to time, by the selling sto |
|
| November 9, 2022 |
AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT & AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT This AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT (the ?Development Amendment?) and AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT (the ?License Amendment?, and collectively with the Development Amendment, this ?Amendment?) is effective a |
|
| November 9, 2022 |
2022, between Lonza Sales AG and Context Therapeutics Inc. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENCE AGREEMENT between LONZA SALES AG and CONTEXT THERAPEUTICS INC. |
|
| November 9, 2022 |
As filed with the Securities and Exchange Commission on November 9, 2022 As filed with the Securities and Exchange Commission on November 9, 2022 Registration No. |
|
| November 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Context Therapeutics Inc. |
|
| November 9, 2022 |
Exhibit 4.3 CONTEXT THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section 2.2. E |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX |
|
| November 9, 2022 |
As filed with the Securities and Exchange Commission on November 9, 2022. POS AM 1 contexttherapeuticsposamno.htm POS AM As filed with the Securities and Exchange Commission on November 9, 2022. Registration No. 333-261599 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in |
|
| November 9, 2022 |
November 2022 Corporate Presentation Advancing Medicines for Female Cancers Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| November 9, 2022 |
EX-10.3 3 lonzacontextdmsa.htm EX-10.3 CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Development and Manufacturing Services Agreement between Lonza Sales AG and Lonza AG and Context Therapeutics Inc. 1 CONFIDENTIAL THIS DEVELOPMENT AND |
|
| November 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| October 27, 2022 |
CNTX / Context Therapeutics Inc. / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 21077P108 (CUSIP Number) January 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| September 27, 2022 |
Context Therapeutics? Amends Cash Guidance, Extends Runway into Q1 2024 Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND PHILADELPHIA, PA? September 27, 2022?Context Therapeutics Inc. |
|
| September 27, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi |
|
| September 27, 2022 |
September 2022 Corporate Presentation Advancing Medicines for Female Cancers Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| August 11, 2022 |
AMENDMENT NO. 2 TO CONSULTING AGREEMENT This AMENDMENT NO. 2 TO CONSULTING AGREEMENT (this ?Amendment?) is entered into as of the 17th day of June 2022, but effective as of the 1st day of June, 2022 (the ?Amendment Effective Date?), and is entered into by and between OncoStrategy LLC, (?Provider?) and Context Therapeutics Inc., a Delaware corporation, having its principal place of business at 2001 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE |
|
| August 11, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto |
|
| August 11, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this ?Agreement?), made as of 1 August, 2022 (the ?Effective Date?), is by and between Context Therapeutics Inc. |
|
| August 2, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 1 Date of Report (Date of earliest event reported): August 1, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| August 2, 2022 |
Corporate Presentation August 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| August 2, 2022 |
EX-99.1 2 contextandmenarinirelease-.htm EX-99.1 Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA, PA and FLO |
|
| June 3, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. 424B3 1 prosuppfor8-kjune32022a.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the “Prospectus”), related to the disposit |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH |
|
| May 11, 2022 |
Form of Common Stock Purchase Warrant. EX 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third Avenue, 20th Floor New York, NY 10022 (Name, Add |
|
| April 12, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 110 of up to 10,000,000 shares of our common stock. The selling stockholders or their permitted trans |
|
| April 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 4, 2022 |
As filed with the Securities and Exchange Commission on April 4, 2022. As filed with the Securities and Exchange Commission on April 4, 2022. Registration No. 333-261599 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3738787 (State or other jurisdic |
|
| March 23, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated December 17, 2021) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 17, 2021 (the ?Prospectus?), related to the disposition, from time to time, by the selli |
|
| March 23, 2022 |
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into effective as of this 22nd day of October, 2021 (?Effective Date?) by and between Context Therapeutics Inc. |
|
| March 23, 2022 |
Context Therapeutics? Reports Full Year 2021 Operating and Financial Results Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28. |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci |
|
| March 23, 2022 |
2022, between OncoStrategy, LLC and Context Therapeutics Inc. AMENDMENT NO. 1 TO CONSULTING AGREEMENT This AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this ?Amendment?) is entered into as of the 21st day of March 2022, but effective as of the 1st day of February, 2022 (the ?Amendment Effective Date?), and is entered into by and between OncoStrategy LLC, (?Provider?) and Context Therapeutics Inc., a Delaware corporation, having its principal place of business at |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio |
|
| March 23, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC. |
|
| March 23, 2022 |
As Filed with the Securities and Exchange Commission on March 23, 2022 As Filed with the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| February 2, 2022 |
CNTX / Context Therapeutics Inc. / Hudson Bay Capital Management LP - CNTX 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 11, 2022 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 17, 2021) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 17, 2021 (the ?Prospectus?), related to the disposition, from time to time, by the selli |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss |
|
| January 10, 2022 |
Corporate Presentation January 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement. |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 5, 2022 |
Context Therapeutics? Strengthens Research & Development Team Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph. |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi |
|
| January 5, 2022 |
MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (this ?Agreement?) is entered into and effective as of January 1, 2022 (the ?Effective Date?) by and between Drug and Device Development Solutions LLC, a North Carolina Limited Liability Corporation, having its principal place of business at [***] (?Provider?), and Context Therapeutics Inc. |
|
| January 5, 2022 |
Statement of Work No. 1 Provider Services Statement of Work No. 1 Provider Services This SOW (?SOW?), dated as of January 1, 2022 (the ?SOW Effective Date?), is subject to that certain Master Services Agreement, effective as of January 1, 2022 (the ?Agreement?), by and between Drug and Device Development Solutions LLC, a North Carolina Limited Liability Corporation, having its principal place of business at [***] (?Provider?), and Context |
|
| December 17, 2021 |
10,000,000 Shares Common Stock Context Therapeutics Inc. Filed Pursuant to Rule 424(b)(4) Registration No. 333-261599 PROSPECTUS 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 113 of up to 10,000,000 shares of our common stock. The selling stockholders or their permitted trans |
|
| December 14, 2021 |
December 14, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| December 10, 2021 |
As filed with the Securities and Exchange Commission on December 10, 2021. As filed with the Securities and Exchange Commission on December 10, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2566423 (State or other jurisdiction of incorporation or organizatio |
|
| December 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss |
|
| December 6, 2021 |
Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement EX-99.1 2 contextclosingpressrelease.htm EX-99.1 Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement PHILADELPHIA, PA - December 6, 2021 (GLOBE NEWSWIRE) - Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological can |
|
| December 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss |
|
| December 2, 2021 |
EX-4.1 2 cntx-20210930x10qexhibit41.htm EX-4.1 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR |
|
| December 2, 2021 |
EX-10.4 4 cntx-20210930x10qexhibit104.htm EX-10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 1, 2021, by and between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agre |
|
| December 2, 2021 |
EX-10.3 3 cntx-20210930x10qexhibit103.htm EX-10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 1, 2021, between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WH |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX |
|
| December 2, 2021 |
Context Therapeutics? Reports Third Quarter 2021 Operating and Financial Results Entered into $31. |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss |
|
| November 1, 2021 |
EX-10.1 2 jminaiemploymentagreementc.htm EX-10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 1st day of November, 2021 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Jennifer Minai-Azary (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capit |
|
| November 1, 2021 |
EX-99.1 3 contextcfocloannouncement1.htm EX-99.1 Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer - Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO - PHILADELPHIA, PA—November 1, 2021—Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherap |
|
| October 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss |
|
| October 22, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on October 21, 2021 and effective as of the closing of the Company?s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance N |
|
| October 22, 2021 |
EX-3.1 2 d251040dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a company organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is Context Therapeutics Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of Sta |
|
| October 22, 2021 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into effective as of this 22nd day of October, 2021 (?Effective Date?) by and between Context Therapeutics, Inc. (the ?Company?) and Martin Lehr (?Executive?). The Company and Executive are each referred to herein as a ?Party? or together as the ?Parties.? Capital |
|
| October 20, 2021 |
As Filed with the Securities and Exchange Commission on October 20, 2021 As Filed with the Securities and Exchange Commission on October 20, 2021 Registration No. |
|
| October 20, 2021 |
ThinkEquity The date of this prospectus is October 19, 2021 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-256572 PROSPECTUS 5,000,000 Shares Common Stock Context Therapeutics Inc. This is the initial public offering of shares of common stock of Context Therapeutics Inc. We currently operate as a Delaware corporation under the name Context Therapeutics Inc. Prior to this offering, there has been no public market for our common stoc |
|
| October 18, 2021 |
Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated October 15, 2021 Relating to the Preliminary Prospectus dated October 15, 2021 Registration Statement File No. |
|
| October 18, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 15, 2021 |
October 15, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| October 15, 2021 |
October 15, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 29, 2021 |
Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 29, 2021 Relating to the Preliminary Prospectus dated September 29, 2021 Registration Statement File No. |
|
| September 29, 2021 |
As filed with the Securities and Exchange Commission on September 29, 2021. Table of Contents As filed with the Securities and Exchange Commission on September 29, 2021. |
|
| September 24, 2021 |
Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 24, 2021 Relating to the Preliminary Prospectus dated September 24, 2021 Registration Statement File No. |
|
| September 24, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR September 24, 2021 Ada Sarmento Tim Buchmiller U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Amendment No. 4 |
|
| September 24, 2021 |
As filed with the Securities and Exchange Commission on September 24, 2021. Table of Contents As filed with the Securities and Exchange Commission on September 24, 2021. |
|
| September 13, 2021 |
context t h er ap eu t i c s Appendix 35 Nasdaq: CNTXcontext t h er ap eu t i c s Appendix 35 Nasdaq: CNTX Appendix Abbreviations AR Androgen Receptor ctDNA Circulating tumor DNA ER Estrogen receptor ESR1 Estrogen receptor 1 gene Ful Fulvestrant GR Glucocorticoid Receptor MAPK Mitogen activated protein kinase mBCa Metastatic breast cancer ONA-IR Onapristone immediate release ONA-XR Onapristone ext |
|
| September 13, 2021 |
Exhibit 10.5 CONFIDENTIAL TREATMENT REQUESTED – REDACTED COPY LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT This LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT (this “Agreement”) is entered into as of August 23, 2021 (the “Effective Date”) by and between Context Therapeutics LLC, a Delaware limited liability company having its registered offices at 3675 Market Street, Suite |
|
| September 13, 2021 |
As filed with the Securities and Exchange Commission on September 10, 2021. S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 10, 2021. |
|
| August 2, 2021 |
August 2, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 2, 2021 |
August 2, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| July 23, 2021 |
July 23, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| July 23, 2021 |
As filed with the Securities and Exchange Commission on July 23, 2021. Table of Contents As filed with the Securities and Exchange Commission on July 23, 2021. |
|
| July 23, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 23, 2021 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Registration Statement o |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-2566423 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) |
|
| July 23, 2021 |
July 23, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 12, 2021 |
Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. |
|
| July 12, 2021 |
Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. |
|
| July 2, 2021 |
Form of Underwriting Agreement. EX-1.1 2 d46596dex11.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between Context Therapeutics Inc. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters Context Therapeutics Inc. UNDERWRITING AGREEMENT New York, New York [●], 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters nam |
|
| July 2, 2021 |
Certificate of Amendment to the Certificate of Incorporation. Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The Certificate of Incorporation of the Corporation is hereby amended by inserting the following paragraph immediately follo |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 1, 2021. Table of Contents As filed with the Securities and Exchange Commission on July 1, 2021. |
|
| July 2, 2021 |
Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 1, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. |
|
| July 1, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 1, 2021 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Registration Statement on |
|
| July 1, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 1, 2021 FOIA Confidential Treatment Request Under 17 C.F.R. ?200.83 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context |
|
| June 16, 2021 |
EX-3.3 2 d46596dex33.htm EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a company organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is Context Therapeutics Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of Stat |
|
| June 16, 2021 |
EX-3.5 3 d46596dex35.htm EX-3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on , 2021 and effective as of the closing of the Company’s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special M |
|
| June 16, 2021 |
As filed with the Securities and Exchange Commission on June 16, 2021. As filed with the Securities and Exchange Commission on June 16, 2021. Registration No. 333-256572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2566423 (State or other jurisdiction of incorpo |
|
| June 16, 2021 |
EX-10.4 4 d46596dex104.htm EX-10.4 Exhibit 10.4 AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT This AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 3rd day of June, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke Road, Building 1 West Wing, Zhan |
|
| June 16, 2021 |
Exhibit 10.10 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 2021 by and between Context Therapeutics Inc., a Delaware corporation (the ?Corporation?), in its own name and on behalf of its direct and indirect subsidiaries, and , an individual (?Indemnitee?). This Agreement supersedes and replaces any and all previous agreements between the Corporation a |
|
| May 27, 2021 |
Bylaws of Context Therapeutics Inc., as currently in effect. Exhibit 3.3 BYLAWS OF CONTEXT THERAPEUTICS INC. (Effective as of April 14, 2021) ARTICLE I OFFICES, CORPORATE SEAL Section 1.01 Registered Office. The registered office of the corporation in Delaware shall be that set forth in the Certificate of Incorporation or in the most recent amendment of the Certificate of Incorporation or in a certificate filed with the Secretary of State of the State of De |
|
| May 27, 2021 |
Voting Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors. Exhibit 4.4 EXECUTION VERSION VOTING AGREEMENT TABLE OF CONTENTS Page 1. Voting Provisions Regarding the Management Committee. 1 1.1 Units Entitled to Vote for Management Committee 1 1.2 Management Committee Composition 1 1.3 Failure to Designate a Management Committee Member 2 1.4 Removal of Management Committee Members 2 1.5 No Liability for Election of Recommended Managers 3 1.6 No ?Bad Actor? |
|
| May 27, 2021 |
Exhibit 4.2 EXECUTION VERSION INVESTORS? RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 8 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnification 9 2.9 Reports Under Exchange Act 11 2.10 Limitations o |
|
| May 27, 2021 |
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.1 RESEARCH COLLABORATION AND LICENSE AGREEMENT FOR CLAUDIN 6 BISPECIFIC ANTIBODIES BY AND BETWEEN CONTEXT THERAPEUTICS, LLC and INTEGRAL MOLECULAR, INC. APRIL 6, 2021 Certain identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. |
|
| May 27, 2021 |
Exhibit 10.6 CONTEXT THERAPEUTICS INC. 2021 LONG-TERM PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF THE PLAN This 2021 Long-Term Performance Incentive Plan (the ?Plan?) is being established to (a) provide incentives and awards to nonemployee directors, consultants and those employees largely responsible for the long-term success of Context Therapeutics Inc. (the ?Company?) and its 50% or more owned sub |
|
| May 27, 2021 |
Powers of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on May 27, 2021. |
|
| May 27, 2021 |
Consulting Agreement, dated October 23, 2019, between William Rencher and Context Therapeutics LLC CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.10 Context Therapeutics, Inc. 3001 Market Street, Suite 140 Philadelphia, PA 19104 Martin Lehr Chief Executive Officer DATE: October 23, 2019 TO: William F. Rencher, RPh., Ph.D. RE: Letter of Engagement This Letter of Engagement (?LOE?) will serve as the basis under which Drug and Device Development Solutions LLC, a North Carolina Limited |
|
| May 27, 2021 |
Exhibit 10.7 Context Therapeutics Inc. 2021 Long -Term Performance Incentive Plan Stock Option Agreement 1. A Stock Option (the ?Option?) for a total of shares of $0.001 par value per share of Common Stock (the ?Stock?) of Context Therapeutics Inc. (the ?Company?), is hereby granted to (the ?Optionee?), subject to the terms and provisions of the Context Therapeutics Inc. 2021 Long-Term Performance |
|
| May 27, 2021 |
Exhibit 4.3 EXECUTION VERSION RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Agreement Among the Company and the Investors 3 2.1 Right of First Refusal 3 2.2 Right of Co-Sale 5 2.3 Effect of Failure to Comply 7 3. Exempt Transfers 7 3.1 Exempted Transfers 7 3.2 Exempted Offerings 8 4. Legend 8 5. Lock-Up 9 5.1 Agreement to Lock-Up 9 5.2 Stop Transfer Instru |
|
| May 27, 2021 |
Exhibit 4.1 DELAWARE SEAL CONTEXT THERAPEUTICS INC. CORPORATE April 20, 2021 CT FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Context Therapeutics Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agen |
|
| May 27, 2021 |
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.12 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?), dated as of May 7, 2021 (the ?Effective Date?), is made by and between Context Therapeutics Inc., Delaware corporation (?Company?), and OncoStrategy, LLC, with its registered address at 4203 Greenspire Lane, New Hope, PA 18938 (hereinafter ?you? or ?Consultant??). PREAMB |
|
| May 27, 2021 |
Exhibit 10.13 BOARD OF DIRECTOR SERVICES AGREEMENT This BOARD OF DIRECTOR SERVICES AGREEMENT (the ?Agreement?) is made and entered into effective as of this 5th day of March 2021 (the ?Effective Date?), by and between Context Therapeutics LLC, a Delaware limited liability company, which is expected to be converted to a Delaware corporation pursuant to a statutory conversion and change its name to |
|
| May 27, 2021 |
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.4 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of December 15, 2017 (the ?Agreement Date?), is entered into by and between Context Biopharma Inc., a Delaware corporation (?Buyer?), and ARNO THERAPEUTICS, INC., a Delaware corporation (?Seller?). Buyer and Seller are referred to collectively herein as |
